32 articles

Safety and side effects, separated from the headlines

A labeled warning and a measured rate are different objects, and most reporting on these drugs runs them together. These articles keep them apart: what each label requires be disclosed, what the trial record actually counted, where the human evidence disagrees with itself, and which symptoms mean a same-day call to a clinician rather than more reading.

  1. Is Compounded Tirzepatide Safe? What FDA Has Actually Reported

    FDA has never reviewed compounded tirzepatide for safety, effectiveness or quality. That is a fact about regulatory review, not a finding of harm. This covers what the agency has reported, what separates a 503A pharmacy from a 503B facility, and what nobody can tell you.

    11 min read · 10 citations
  2. Compounded Tirzepatide Side Effects: The Drug, and the Vial

    Most compounded tirzepatide side effects are tirzepatide side effects, documented in the approved product's label and trials. A smaller set comes from the preparation: a pharmacy-set concentration, added ingredients, and an adverse-event pathway that may never count your report.

    10 min read · 7 citations
  3. Tirzepatide Long-Term Side Effects: Where the Evidence Stops

    The longest published randomized tirzepatide treatment in obesity is 176 weeks, and the cardiovascular trial ran a median of 46.9 months. This separates what the approved label warns about from what a trial counted, and says where the record ends.

    11 min read · 11 citations
  4. How Long Do Semaglutide and Tirzepatide Side Effects Last?

    What predicts side effects is where you are on the ladder, not how many weeks you have been taking it. Both labels place the nausea and diarrhea during escalation, and how long any single dose keeps working comes down to half-life: roughly seven days for semaglutide, roughly five for tirzepatide.

    11 min read · 8 citations
  5. GLP-1 Thyroid Cancer Risk: What the Boxed Warning Actually Says

    A boxed warning about thyroid C-cell tumors sits on every semaglutide and tirzepatide label there is. It comes from rodent studies, the labels themselves say the human relevance is undetermined, and the human research published since does not agree with itself.

    11 min read · 13 citations
  6. GLP-1 Eye Risks: Diabetic Retinopathy and NAION Are Not the Same Thing

    Two distinct eye questions get merged into one headline. Diabetic retinopathy complications are on the semaglutide label and trace to blood sugar falling fast; NAION is a separate optic-nerve signal that Europe's drug-safety committee recommended adding to product information in June 2025, and US labeling still does not mention.

    12 min read · 17 citations
  7. GLP-1 Pancreatitis and Gallbladder Risk: What the Labels Counted

    Two labeled warnings that are not the same kind of problem. Gallbladder disease tracks with rapid weight loss and is well counted; pancreatitis is rarer, was an exclusion criterion in the pivotal trials, and the database studies disagree.

    12 min read · 19 citations
  8. GLP-1 Hair Loss and Muscle Loss: What Was Measured

    Hair shedding and lean-mass loss both appear in the trial record, and both are mostly consequences of losing weight quickly rather than of the drug. That is reassuring about mechanism and not reassuring about outcome, and this holds both.

    11 min read · 16 citations
  9. GLP-1s and Hormonal Birth Control: Which Labels Carry the Warning

    Three of six GLP-1 labels warn about the contraceptive pill. Mounjaro and Zepbound set a four-week window after starting and after every dose increase, and Foundayo a 30-day one; the three semaglutide labels carry no such advisory. We read all six.

    9 min read · 9 citations
  10. GLP-1s, Pregnancy and Trying to Conceive: What the Labels Say

    If you are pregnant or might be, this is a conversation with a clinician. What this sets out is the text behind it: each label's own wording on pregnancy, on the interval before a planned one, and on breastfeeding, plus where the human evidence is thin.

    11 min read · 13 citations
  11. What Happens When You Stop a GLP-1: What the Withdrawal Trials Measured

    Three trials took semaglutide or tirzepatide away from people who had lost weight on it, two of them by random assignment, and measured what came back: the weight, and the cardiometabolic gains with it.

    11 min read · 12 citations
  12. GLP-1 Overdose: What Happens and What to Do

    Most GLP-1 overdoses are dosing mistakes with compounded vials and cause severe nausea and vomiting that can last days. The guidance on the Ozempic, Wegovy, Mounjaro and Zepbound labels, FDA's dosing-error alert, and when to call Poison Help or 911.

    10 min read · 17 citations
  13. Stopping Ozempic or Wegovy: Side Effects, Weight Regain and Keeping It Off

    Stopping Ozempic or Wegovy causes no withdrawal syndrome on either label. Appetite returns as semaglutide clears over about five weeks, and a 2026 BMJ meta-analysis found regain of about 0.8 kg a month. What helps keep weight off, and what women should know.

    10 min read · 10 citations
  14. Stopping Tirzepatide (Zepbound): Weight Regain, Side Effects and Cold Turkey

    In SURMOUNT-4, people switched from tirzepatide to placebo regained 14% of body weight in a year, most of it in the first six months. What the Zepbound label says about stopping, the 5-day half-life, diabetes, and what helps keep weight off.

    11 min read · 11 citations
  15. Does Ozempic Slow Your Metabolism? What the Measurements Show

    Ozempic does not slow metabolism beyond what weight loss itself does. Calorimetry studies of semaglutide and tirzepatide found the drop in calorie burn matched the lost weight, and was no bigger than with dieting. What happens to muscle, plateaus and metabolism after stopping.

    11 min read · 20 citations
  16. Intermittent Fasting on a GLP-1: What Has Been Tested and What Has Not

    No trial has added intermittent fasting or a 16:8 eating window to semaglutide or tirzepatide. What the fasting trials show on their own, and the risks that matter on a GLP-1: protein, low blood sugar, fluids, the oral tablet's morning rule and gallstones.

    10 min read · 18 citations
  17. Ozempic and Gastroparesis: How Real Is “Stomach Paralysis”?

    GLP-1 users are diagnosed with gastroparesis more often, about 6.5 per 1,000 a year on semaglutide against 2.1 on another weight drug. What the Ozempic and Mounjaro labels added and when, whether it reverses, and where MDL 3094 stands.

    11 min read · 26 citations
  18. Can Ozempic or Mounjaro Cause Liver Damage? Liver Enzymes Evidence Review

    Liver injury on semaglutide or tirzepatide is rare. Trial ALT levels fall on average, no label carries a liver warning, and about 31 suspected cases have been published. Gallstones are the likelier cause of a raised liver test, and jaundice or dark urine needs same-day care.

    11 min read · 29 citations
  19. GLP-1 Drugs and Kidney Stones: What the Labels and Studies Show

    No trial was designed to test whether Ozempic, Wegovy, Mounjaro or Zepbound cause kidney stones. Wegovy's label reports urinary stones in 1.2% vs 0.8% on placebo in a heart trial; the other labels are silent. What the cohorts, urine studies and fluid data show.

    10 min read · 23 citations
  20. Does Ozempic Make You Pee More? GLP-1 Drugs, Urination and Thirst

    GLP-1 drugs push extra sodium into the urine for a few hours, but after weeks on a weekly shot, trials found less urine because people drank less. Frequent urination and thirst are not on any GLP-1 label. What usually causes them instead.

    11 min read · 20 citations
  21. GLP-1 Allergic Reactions and Anaphylaxis: What the Labels and Cases Show

    True allergy to semaglutide or tirzepatide is real but rare: about 3.6 anaphylaxis cases per 10,000 person-years on semaglutide. What each label says, how antibodies and inactive ingredients fit in, whether another GLP-1 is safe after a reaction, and when to call 911.

    11 min read · 20 citations
  22. GLP-1 Skin Sensitivity, Rash and Itching: What the Labels Record

    Skin that hurts to touch and skin that itches are two different GLP-1 reactions. Burning or tender skin is a dose-related semaglutide effect, rare on tirzepatide; rash and itching sit in the allergy column, higher on Zepbound and Mounjaro. When it is an emergency.

    11 min read · 22 citations
  23. Does Ozempic or Mounjaro Cause Anxiety? What the Trials and Labels Show

    In randomized trials, anxiety was no more common on semaglutide or tirzepatide than on placebo. Where cohort studies and adverse-event reports disagree, why low blood sugar and a faster pulse can feel like anxiety, and what is known about panic attacks.

    12 min read · 23 citations
  24. Ozempic Brain Fog: What the Labels, Trials and Reports Show

    Brain fog is not a listed side effect on the Ozempic, Wegovy, Mounjaro or Zepbound labels, and trials that tested thinking on GLP-1 drugs found no harm. The label-backed suspects are fatigue, dehydration, low blood sugar and too little food.

    9 min read · 14 citations
  25. Ozempic Dreams and Nightmares: What the Evidence Shows

    No study has measured dreams on Ozempic, Wegovy, Mounjaro or Zepbound, and none of the labels lists abnormal dreams or nightmares. What FDA reports, signal studies and sleep research do show, and when night-time low blood sugar is the real cause.

    9 min read · 14 citations
  26. Feeling Cold and Night Sweats on a GLP-1: What the Labels and Studies Show

    No GLP-1 label lists feeling cold, chills or night sweats, and no study has measured body temperature on Ozempic or Mounjaro. What weight loss does to temperature, why sweating can mean low blood sugar, and when the thyroid is the cause.

    11 min read · 28 citations
  27. Ozempic and Smell: Sensitivity, Food Aversion, Urine and Body Odor

    No GLP-1 label lists a smell change, and smell tests in users show no significant loss, yet a 438,474-pair records study found 1.81 times the smell diagnoses. Why urine, breath and sweat can smell different, and when it matters.

    10 min read · 30 citations
  28. Ozempic, Mounjaro and Tinnitus: What the Hearing Evidence Shows

    No GLP-1 label lists tinnitus, vertigo or hearing loss, and no trial has measured them. FAERS reports, cohort studies of coded diagnoses, the open-Eustachian-tube problem that fast weight loss causes, and when sudden hearing loss is an emergency.

    11 min read · 26 citations
  29. GLP-1 Bowel Obstruction and Ileus: Label Warning and Evidence Review

    Ileus and intestinal obstruction are listed on the Ozempic, Wegovy, Mounjaro and Zepbound labels as postmarketing reports with no rate. What the 2023 JAMA signal really showed, what larger cohorts and the SELECT trial found, the warning signs, and where the lawsuits stand.

    11 min read · 28 citations
  30. Blurred Vision on Ozempic or Mounjaro: Causes, How Long It Lasts, When It's Urgent

    Blurred vision on Ozempic or Mounjaro that comes from blood sugar falling fast shifts the lens's focus for weeks, then settles. Retinopathy worsening and NAION do not clear on their own. What the labels list, how long each cause lasts, and when to get same-day care.

    11 min read · 21 citations
  31. Foundayo (Orforglipron) Side Effects: Rates by Dose, Dropouts and Interactions

    Foundayo's side effects are mostly digestive and rise with dose: nausea in 26% to 35% vs 10% on placebo, and 10% quit at the top dose. The FDA label's full table, when effects ease, serious risks, CYP3A4 interactions, and how it compares with the Wegovy pill and injections.

    11 min read · 13 citations
  32. Which Zepbound Dose Works Best? 5, 10 and 15 mg Compared in the Trials

    In SURMOUNT-1, Zepbound 15 mg averaged 20.9% weight loss, 10 mg 19.5% and 5 mg 15.0%. The step from 10 to 15 mg added 1.4 points. Results, side effects and discontinuation by dose, the 15 mg maximum, and why the label counts 5, 10 and 15 mg as maintenance.

    10 min read · 7 citations